Background & Objective: Access to CGM for people with type 2 diabetes (T2D) remains limited, especially for those treated in the primary care setting. The objective of this study, a collaboration between a primary care practice and the local public health department, was to evaluate the glycemic impact of CGM access on adults with T2D.
Methods: CGM systems (Dexcom G6 and G7) were provided to eligible participants with T2D who were ≥18 years of age, CGM-naïve, and did not have health insurance coverage for CGM. Outcomes included changes in A1C and CGM metrics from baseline to one year.
Results: Participants (n=177) were (mean ± SD) 59.1 ± 12.0 years, 41.2% female, BMI 35.5 ± 8.5, duration of diabetes 11.1 ± 9.3 years. After one year, A1C decreased from 9.4% ± 1.6 to 7.1% ± 1.3 (-2.3% ± 1.9, p<0.001). The proportion of participants meeting the ADA target of A1C <7.0% increased from n=1 (0.6%) at baseline to n=91 (51.4%) at one year. Those meeting the HEDIS target of A1C <8.0% increased from 19.2% at baseline to 85.9% at one year. CGM outcomes (n=109) after near-continuous use included an increase in TIR of 9.9% ± 29.4 (p<0.001) and a large increase in TITR (p<0.001, Table).
Conclusion: Self-guided use of CGM by primary care patients with T2D for one year was associated with clinically meaningful improvements in A1C and TIR.
T. Grace: Speaker's Bureau; Sanofi, Novo Nordisk, Eli Lilly and Company, Dexcom, Inc. Employee; Dexcom, Inc. J.E. Layne: Employee; Dexcom, Inc. Stock/Shareholder; Dexcom, Inc. Employee; Verily Life Sciences. C. Hicks: Employee; Dexcom, Inc. C.R. Green: Employee; Dexcom, Inc. T.C. Walker: Employee; Dexcom, Inc. Stock/Shareholder; Dexcom, Inc.
